secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001104659-23-059297
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Q1 loss widens to $11.3M; positive Ph1b/2a data for AP-PA02; closes $30M convertible
--------------------------------------------------------------------------------

- Positive topline data from AP-PA02 Ph1b/2a in cystic fibrosis; first patient dosed in Phase 2 NCFB study.
- AP-SA02 advanced: second cohort dosed in Staphylococcus aureus bacteremia Ph1b/2a; PJI study start-up activities.
- Closed $30M secured convertible credit agreement with Innoviva (largest shareholder) to fund trials and manufacturing.
- Q1 loss from operations $(11.3)M vs $(8.8)M a year ago; cash $25.1M vs $14.9M at Dec 31, 2022.
- Grant revenue $0.8M from MTEC/DoD; $16.3M total grant funding expected for AP-SA02 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/0001104659-23-059297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465923059297/tm2315601d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer